{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:21:36Z","timestamp":1783560096276,"version":"3.55.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01283-4","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:22:43Z","timestamp":1780302163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies"],"prefix":"10.1007","volume":"26","author":[{"given":"Geetha","family":"J","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathiya","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickram","family":"A S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"10258","key":"1283_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"Global burden","year":"2020","unstructured":"Global burden. of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"key":"1283_CR2","unstructured":"http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma."},{"issue":"1","key":"1283_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.23736\/S0026-4806.21.07332-8","volume":"113","author":"V Fainardi","year":"2022","unstructured":"Fainardi V, Esposito S, Chetta A, Pisi G. Asthma phenotypes and endotypes in childhood. Minerva Med. 2022;113(1):94\u2013105. https:\/\/doi.org\/10.23736\/S0026-4806.21.07332-8.","journal-title":"Minerva Med"},{"issue":"4","key":"1283_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.anai.2018.06.009","volume":"121","author":"R Scherzer","year":"2018","unstructured":"Scherzer R, Grayson MH. Heterogeneity and the origins of asthma. Annals allergy asthma immunology: official publication Am Coll Allergy Asthma Immunol. 2018;121(4):400\u20135. https:\/\/doi.org\/10.1016\/j.anai.2018.06.009.","journal-title":"Annals allergy asthma immunology: official publication Am Coll Allergy Asthma Immunol"},{"key":"1283_CR5","doi-asserted-by":"crossref","unstructured":"Fuhlbrigge AL, Sharma S. Unraveling the heterogeneity of asthma: decoding subtypes of asthma. J Allergy Clin Immunol. 2025;156(1):41\u201350.","DOI":"10.1016\/j.jaci.2025.03.008"},{"issue":"7","key":"1283_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/jpm12071093","volume":"12","author":"K Porpodis","year":"2022","unstructured":"Porpodis K, Tsiouprou I, Apostolopoulos A, Ntontsi P, Fouka E, Papakosta D, Domvri K. Eosinophilic asthma, phenotypes-endotypes and current biomarkers of choice. J Pers Med. 2022;12(7):1093.","journal-title":"J Pers Med"},{"issue":"6","key":"1283_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/biomedicines13061342","volume":"13","author":"MI Reza","year":"2025","unstructured":"Reza MI, Ambhore NS. Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic Frontiers. Biomedicines. 2025;13(6):1342.","journal-title":"Biomedicines"},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"974066","DOI":"10.3389\/fimmu.2022.974066","volume":"13","author":"W Luo","year":"2022","unstructured":"Luo W, Hu J, Xu W, Dong J. Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Front Immunol. 2022;13:974066. https:\/\/doi.org\/10.3389\/fimmu.2022.974066.","journal-title":"Front Immunol"},{"issue":"1","key":"1283_CR9","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1111\/imr.70010","volume":"330","author":"SE van Olsthoorn","year":"2025","unstructured":"Olsthoorn SE, van Krimpen A, Hendriks RW, Stadhouders R. Chronic inflammation in asthma: looking beyond the Th2 cell. Immunol Rev. 2025;330(1):e70010.","journal-title":"Immunol Rev"},{"issue":"2","key":"1283_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2021.12.769","volume":"149","author":"Y Xie","year":"2022","unstructured":"Xie Y, Abel PW, Casale TB, Tu Y. TH17 cells and corticosteroid insensitivity in severe asthma. J Allergy Clin Immunol. 2022;149(2):467\u201379. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.769.","journal-title":"J Allergy Clin Immunol"},{"key":"1283_CR11","doi-asserted-by":"publisher","first-page":"112189","DOI":"10.1016\/j.intimp.2024.112189","volume":"134","author":"B Sun","year":"2024","unstructured":"Sun B, Shen K, Zhao R, Li Y, Xiang M, Lin J. Precision medicine for severe asthma\u2013Biological targeted therapy. Int Immunopharmacol. 2024;134:112189.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"1283_CR12","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.3390\/jcm14093153","volume":"14","author":"N Faria","year":"2025","unstructured":"Faria N, Costa MI, Fernandes AL, Fernandes A, Fernandes B, Machado DC, Machado F, Sim\u00e3o L, Ribeiro L, Ferreira L, Boaventura R, Lima R, Ferreira J. Biologic Therapies for Severe Asthma: Current Insights and Future Directions. J Clin Med. 2025;14(9):3153. https:\/\/doi.org\/10.3390\/jcm14093153.","journal-title":"J Clin Med"},{"issue":"1","key":"1283_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.alit.2025.10.001","volume":"75","author":"Y Hamada","year":"2026","unstructured":"Hamada Y, Thomas D, McDonald VM, Fricker M, Heaney LG, Gibson PG. Clinical remission in severe asthma treated with biologics and macrolides: Definition, prevalence, associated factors, and future perspectives. Allergology Int. 2026;75(1):15\u201325.","journal-title":"Allergology Int"},{"key":"1283_CR14","unstructured":"Sinyor B, Perez LC. Pathophysiology of asthma. StatPearls. StatPearls Publishing; 2023."},{"issue":"6","key":"1283_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2021","unstructured":"Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(6):1469\u201385.","journal-title":"Cell"},{"issue":"11","key":"1283_CR16","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/biomedicines9111684","volume":"9","author":"FLM Ricciardolo","year":"2021","unstructured":"Ricciardolo FLM, Sprio AE, Baroso A, Gallo F, Riccardi E, Bertolini F, Carriero V, Arrigo E, Ciprandi G. Characterization of T2-Low and T2-High Asthma Phenotypes in Real-Life. Biomedicines. 2021;9(11):1684. https:\/\/doi.org\/10.3390\/biomedicines9111684.","journal-title":"Biomedicines"},{"issue":"5","key":"1283_CR17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/diagnostics12051175","volume":"12","author":"A Yamasaki","year":"2022","unstructured":"Yamasaki A, Okazaki R, Harada T. Neutrophils and Asthma. Diagnostics (Basel Switzerland). 2022;12(5):1175. https:\/\/doi.org\/10.3390\/diagnostics12051175.","journal-title":"Diagnostics (Basel Switzerland)"},{"issue":"1","key":"1283_CR18","doi-asserted-by":"publisher","first-page":"L71","DOI":"10.1152\/ajplung.00547.2017","volume":"316","author":"RD Britt Jr","year":"2019","unstructured":"Britt RD Jr, Thompson MA, Sasse S, Pabelick CM, Gerber AN, Prakash YS. Th1 cytokines TNF-\u03b1 and IFN-\u03b3 promote corticosteroid resistance in developing human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2019;316(1):L71\u201381. https:\/\/doi.org\/10.1152\/ajplung.00547.2017.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"12","key":"1283_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.it.2017.07.003","volume":"38","author":"A Ray","year":"2017","unstructured":"Ray A, Kolls JK. Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol. 2017;38(12):942\u201354. https:\/\/doi.org\/10.1016\/j.it.2017.07.003.","journal-title":"Trends Immunol"},{"issue":"1","key":"1283_CR20","doi-asserted-by":"publisher","first-page":"e70007","DOI":"10.1111\/imr.70007","volume":"330","author":"ML Ford","year":"2025","unstructured":"Ford ML, Reza MI, Ruwanpathirana A, Sathish V, Britt RD Jr. Integrative Roles of Pro-Inflammatory Cytokines on Airway Smooth Muscle Structure and Function in Asthma. Immunol Rev. 2025;330(1):e70007. https:\/\/doi.org\/10.1111\/imr.70007.","journal-title":"Immunol Rev"},{"key":"1283_CR21","doi-asserted-by":"publisher","first-page":"114292","DOI":"10.1016\/j.bcp.2020.114292","volume":"182","author":"J De Volder","year":"2020","unstructured":"De Volder J, Vereecke L, Joos G, Maes T. Targeting neutrophils in asthma: A therapeutic opportunity? Biochem Pharmacol. 2020;182:114292.","journal-title":"Biochem Pharmacol"},{"key":"1283_CR22","doi-asserted-by":"crossref","unstructured":"Fahy JV, Jackson ND, Sajuthi SP, Pruesse E, Moore CM, Everman JL, Rios C, Tang M, Gauthier M, Wenzel SE, Bleecker ER. Asthma severity and corticosteroid response depend on variable type 1 and type 2 inflammation in the airway. medRxiv. 2023-10.","DOI":"10.1101\/2023.10.05.23296609"},{"issue":"3","key":"1283_CR23","doi-asserted-by":"publisher","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","volume":"8","author":"J Maspero","year":"2022","unstructured":"Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, Lababidi H, Ledanois O, Mahoub B, Perng DW, Vazquez JC, Yorgancioglu A. Type 2 inflammation in asthma and other airway diseases. ERJ open Res. 2022;8(3):00576\u20132021. https:\/\/doi.org\/10.1183\/23120541.00576-2021.","journal-title":"ERJ open Res"},{"issue":"2","key":"1283_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaip.2019.11.020","volume":"8","author":"AM Coverstone","year":"2020","unstructured":"Coverstone AM, Seibold MA, Peters MC. Diagnosis and management of T2-high asthma. J Allergy Clin Immunology: Pract. 2020;8(2):442\u201350.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"1283_CR25","doi-asserted-by":"crossref","unstructured":"Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe PJ, Ruddy M, Castro M. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58(2).","DOI":"10.1183\/13993003.03393-2020"},{"issue":"2","key":"1283_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/all.15609","volume":"78","author":"GM Gauvreau","year":"2023","unstructured":"Gauvreau GM, Bergeron C, Boulet LP, Cockcroft DW, C\u00f4t\u00e9 A, Davis BE, Leigh R, Myers I, O\u2019Byrne PM, Sehmi R. Sounding the alarmins-The role of alarmin cytokines in asthma. Allergy. 2023;78(2):402\u201317. https:\/\/doi.org\/10.1111\/all.15609.","journal-title":"Allergy"},{"issue":"2","key":"1283_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.alit.2022.12.001","volume":"72","author":"A Iwata","year":"2023","unstructured":"Iwata A, Toda Y, Furuya H, Nakajima H. Group 2 innate lymphoid cells in human asthma. Allergology Int. 2023;72(2):194\u2013200.","journal-title":"Allergology Int"},{"issue":"6","key":"1283_CR28","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.3390\/ijms24065716","volume":"24","author":"J Novosad","year":"2023","unstructured":"Novosad J, Kr\u010dmov\u00e1 I, Sou\u010dek O, Draho\u0161ov\u00e1 M, Sedl\u00e1k V, Kul\u00ed\u0159ov\u00e1 M, Kr\u00e1l\u00ed\u010dkov\u00e1 P. Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment. Int J Mol Sci. 2023;24(6):5716. https:\/\/doi.org\/10.3390\/ijms24065716.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1283_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","volume":"56","author":"ME Kuruvilla","year":"2019","unstructured":"Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2019;56(2):219\u201333. https:\/\/doi.org\/10.1007\/s12016-018-8712-1.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"1283_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/genes12060801","volume":"12","author":"S Popovi\u0107-Grle","year":"2021","unstructured":"Popovi\u0107-Grle S, \u0160tajduhar A, Lampalo M, Rnjak D. Biomarkers in Different Asthma Phenotypes. Genes. 2021;12(6):801. https:\/\/doi.org\/10.3390\/genes12060801.","journal-title":"Genes"},{"key":"1283_CR31","doi-asserted-by":"publisher","first-page":"969243","DOI":"10.3389\/fmed.2022.969243","volume":"9","author":"G Guida","year":"2022","unstructured":"Guida G, Bagnasco D, Carriero V, Bertolini F, Ricciardolo FLM, Nicola S, Heffler E. Critical evaluation of asthma biomarkers in clinical practice. Front Med. 2022;9:969243.","journal-title":"Front Med"},{"issue":"3","key":"1283_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.iac.2016.03.004","volume":"36","author":"XC Wan","year":"2016","unstructured":"Wan XC, Woodruff PG. Biomarkers in Severe Asthma. Immunol Allergy Clin North Am. 2016;36(3):547\u201357. https:\/\/doi.org\/10.1016\/j.iac.2016.03.004.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"1283_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4168\/aair.2024.16.5.462","volume":"16","author":"S Sim","year":"2024","unstructured":"Sim S, Choi Y, Park HS. Update on Inflammatory Biomarkers for Defining Asthma Phenotype. Allergy Asthma Immunol Res. 2024;16(5):462\u201372. https:\/\/doi.org\/10.4168\/aair.2024.16.5.462.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"1283_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40733-018-0047-4","volume":"4","author":"A Tiotiu","year":"2018","unstructured":"Tiotiu A. Biomarkers in asthma: state of the art. Asthma Res Pract. 2018;4(1):10.","journal-title":"Asthma Res Pract"},{"key":"1283_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coi.2020.10.002","volume":"66","author":"SN Hudey","year":"2020","unstructured":"Hudey SN, Ledford DK, Cardet JC. Mechanisms of non-type 2 asthma. Curr Opin Immunol. 2020;66:123\u20138. https:\/\/doi.org\/10.1016\/j.coi.2020.10.002.","journal-title":"Curr Opin Immunol"},{"key":"1283_CR36","first-page":"101333","volume":"46","author":"T Boonpiyathad","year":"2019","unstructured":"Boonpiyathad T, S\u00f6zener ZC, Satitsuksanoa P, Akdis CA. December). Immunologic mechanisms in asthma. Seminars in immunology. Academic. 2019;46:101333.","journal-title":"Academic"},{"issue":"6","key":"1283_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40272-014-0107-z","volume":"16","author":"A Licari","year":"2014","unstructured":"Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL. Omalizumab in children. Paediatr Drugs. 2014;16(6):491\u2013502. https:\/\/doi.org\/10.1007\/s40272-014-0107-z.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"1283_CR38","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.waojou.2023.100787","volume":"16","author":"F Menzella","year":"2023","unstructured":"Menzella F, Just J, Sauerbeck IS, Mailaender C, Saccheri F, Thonnelier C, Jaumont X, Mala L. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >\u20091500 IU\/mL. World Allergy Organ J. 2023;16(6):100787. https:\/\/doi.org\/10.1016\/j.waojou.2023.100787.","journal-title":"World Allergy Organ J"},{"issue":"7","key":"1283_CR39","doi-asserted-by":"publisher","first-page":"CD010834","DOI":"10.1002\/14651858.CD010834.pub4","volume":"7","author":"HA Farne","year":"2022","unstructured":"Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):CD010834. https:\/\/doi.org\/10.1002\/14651858.CD010834.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1283_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.mucimm.2024.03.005","volume":"17","author":"J Luo","year":"2024","unstructured":"Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, Hynes G, Klenerman P, Pavord ID, Xue L. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma. Mucosal Immunol. 2024;17(4):524\u201336. https:\/\/doi.org\/10.1016\/j.mucimm.2024.03.005.","journal-title":"Mucosal Immunol"},{"key":"1283_CR41","doi-asserted-by":"publisher","first-page":"1587158","DOI":"10.3389\/fimmu.2025.1587158","volume":"16","author":"M Lazzeroni","year":"2025","unstructured":"Lazzeroni M, Longoni V, Schiavo P, Bizzi E, Brucato A, Gramellini G, Borin M, Dragonetti A, Gaffuri M, Lentini M, Maniaci A, Mauro A, Gidaro A, Schroeder J, Capaccio P. Anti-IL5\/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review. Front Immunol. 2025;16:1587158. https:\/\/doi.org\/10.3389\/fimmu.2025.1587158.","journal-title":"Front Immunol"},{"issue":"6","key":"1283_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40265-024-02037-0","volume":"84","author":"C Lombardi","year":"2024","unstructured":"Lombardi C, Comberiati P, Ridolo E, Cottini M, Yacoub MR, Casagrande S, Ricc\u00f2 M, Bottazzoli M, Berti A. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan. Drugs. 2024;84(6):661\u201384. https:\/\/doi.org\/10.1007\/s40265-024-02037-0.","journal-title":"Drugs"},{"issue":"3","key":"1283_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/lungindia.lungindia_442_24","volume":"42","author":"D Gothi","year":"2025","unstructured":"Gothi D, Narasimhan R, Guleria R, Chopra M, Gvalani A, Hegde R. Improving patient outcomes: Mepolizumab\u2019s impact in IL-5-mediated diseases. Lung India: official organ Indian Chest Soc. 2025;42(3):231\u201344. https:\/\/doi.org\/10.4103\/lungindia.lungindia_442_24.","journal-title":"Lung India: official organ Indian Chest Soc"},{"issue":"1","key":"1283_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12890-024-02885-2","volume":"24","author":"W Li","year":"2024","unstructured":"Li W, Tang SC, Jin L. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments. BMC Pulm Med. 2024;24(1):70.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"1283_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/biom15040544","volume":"15","author":"M Shiomi","year":"2025","unstructured":"Shiomi M, Watanabe R, Ishihara R, Tanaka S, Nakazawa T, Hashimoto M. Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. Biomolecules. 2025;15(4):544. https:\/\/doi.org\/10.3390\/biom15040544.","journal-title":"Biomolecules"},{"issue":"11","key":"1283_CR46","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.3390\/ijms24119563","volume":"24","author":"G Scioscia","year":"2023","unstructured":"Scioscia G, Nolasco S, Campisi R, Quarato CMI, Caruso C, Pelaia C, Portacci A, Crimi C. Switching Biological Therapies in Severe Asthma. Int J Mol Sci. 2023;24(11):9563. https:\/\/doi.org\/10.3390\/ijms24119563.","journal-title":"Int J Mol Sci"},{"key":"1283_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/PROM.S146966","volume":"9","author":"A Padilla Galo","year":"2018","unstructured":"Padilla Galo A, Labor M, Tiotiu A, Baiardini I, Scichilone N, Braido F. Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives. Patient Relat outcome measures. 2018;9:267\u201373. https:\/\/doi.org\/10.2147\/PROM.S146966.","journal-title":"Patient Relat outcome measures"},{"issue":"8","key":"1283_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1753465817717134","volume":"11","author":"J M\u00e1spero","year":"2017","unstructured":"M\u00e1spero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. Ther Adv Respir Dis. 2017;11(8):311\u201325. https:\/\/doi.org\/10.1177\/1753465817717134.","journal-title":"Ther Adv Respir Dis"},{"issue":"9","key":"1283_CR49","first-page":"564","volume":"42","author":"S Hom","year":"2017","unstructured":"Hom S, Pisano M. Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype. P T: peer-reviewed J formulary Manage. 2017;42(9):564\u20138.","journal-title":"P T: peer-reviewed J formulary Manage"},{"issue":"1","key":"1283_CR50","first-page":"176","volume":"4","author":"BS Kumar","year":"2025","unstructured":"Kumar BS, A., Narayan BA, D. Emerging Targeted Therapies in Asthma: Biologics, Small Molecules, and Innovative Inhaled Formulations. Eurasian J Chem Med Petroleum Res. 2025;4(1):176\u201386.","journal-title":"Eurasian J Chem Med Petroleum Res"},{"issue":"5","key":"1283_CR51","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, Bai Y, Lim WK, Martin J, Huang T, Potocky TB, Kim JH, Rafique A, Papadopoulos NJ, Stahl N, Yancopoulos GD, Murphy AJ, Sleeman MA, Orengo JM. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"issue":"9","key":"1283_CR52","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/biomedicines9091096","volume":"9","author":"FLM Ricciardolo","year":"2021","unstructured":"Ricciardolo FLM, Bertolini F, Carriero V. The Role of Dupilumab in Severe Asthma. Biomedicines. 2021;9(9):1096. https:\/\/doi.org\/10.3390\/biomedicines9091096.","journal-title":"Biomedicines"},{"key":"1283_CR53","doi-asserted-by":"publisher","unstructured":"Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse,W. W., Ford, L., Sher, L., FitzGerald, J. M., Katelaris, C., Tohda, Y., Zhang, B.,Staudinger, H., Pirozzi, G., Amin, N., Ruddy, M., Akinlade, B., Khan, A., Chao, J.,\u2026 Teper, A. (2018). Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. The New England journal of medicine, 378(26), 2486\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","DOI":"10.1056\/NEJMoa1804092"},{"issue":"6","key":"1283_CR54","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1183\/09031936.00063510","volume":"37","author":"ST Holgate","year":"2011","unstructured":"Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I. Raible,D. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised,controlled trial. Eur Respir J. 2011;37(6):1352\u20139.","journal-title":"Eur Respir J"},{"key":"1283_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1874306401307010021","volume":"7","author":"C Taill\u00e9","year":"2013","unstructured":"Taill\u00e9 C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, Aubier M. Monoclonal Anti-TNF-\u03b1 Antibodies for Severe Steroid-Dependent Asthma: A Case Series. open respiratory Med J. 2013;7:21\u20135. https:\/\/doi.org\/10.2174\/1874306401307010021.","journal-title":"open respiratory Med J"},{"key":"1283_CR56","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05035862 , accessed on 10\/09\/2025."},{"key":"1283_CR57","doi-asserted-by":"publisher","first-page":"574027","DOI":"10.3389\/fimmu.2020.574027","volume":"11","author":"HE Rich","year":"2020","unstructured":"Rich HE, Antos D, Melton NR, Alcorn JF, Manni ML. Insights into type I and III interferons in asthma and exacerbations. Front Immunol. 2020;11:574027.","journal-title":"Front Immunol"},{"issue":"1","key":"1283_CR58","doi-asserted-by":"publisher","first-page":"e70011","DOI":"10.1111\/imr.70011","volume":"330","author":"M Gauthier","year":"2025","unstructured":"Gauthier M, Kale SL, Ray A. T1-T2 Interplay in the Complex Immune Landscape of Severe Asthma. Immunol Rev. 2025;330(1):e70011. https:\/\/doi.org\/10.1111\/imr.70011.","journal-title":"Immunol Rev"},{"issue":"10","key":"1283_CR59","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Nair P. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797\u2013806.","journal-title":"Lancet Respir Med"},{"key":"1283_CR60","doi-asserted-by":"publisher","first-page":"694514","DOI":"10.3389\/falgy.2021.694514","volume":"2","author":"SF Rahmawati","year":"2021","unstructured":"Rahmawati SF, Velde T, Kerstjens M, D\u00f6mling HAM, Groves ASS, M. R., Gosens R. Pharmacological Rationale for Targeting IL-17 in Asthma. Front allergy. 2021;2:694514. https:\/\/doi.org\/10.3389\/falgy.2021.694514.","journal-title":"Front allergy"},{"issue":"4","key":"1283_CR61","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jaci.2021.08.013","volume":"148","author":"SN Georas","year":"2021","unstructured":"Georas SN, Donohue P, Connolly M, Wechsler ME. JAK inhibitors for asthma. J Allergy Clin Immunol. 2021;148(4):953\u201363. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1283_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.alit.2022.11.006","volume":"72","author":"M Kurihara","year":"2023","unstructured":"Kurihara M, Kabata H, Irie M, Fukunaga K. Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma. Allergology Int. 2023;72(1):24\u201330.","journal-title":"Allergology Int"},{"key":"1283_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/JAA.S342391","volume":"17","author":"R Panettieri Jr","year":"2024","unstructured":"Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. J asthma allergy. 2024;17:219\u201336. https:\/\/doi.org\/10.2147\/JAA.S342391.","journal-title":"J asthma allergy"},{"issue":"23","key":"1283_CR64","doi-asserted-by":"publisher","first-page":"e190240","DOI":"10.1172\/jci.insight.190240","volume":"10","author":"N Morita","year":"2025","unstructured":"Morita N, Yamamoto K, Tamano R, Gao P, Nagatake T, Inomata T, Huang T, Yamada Y, Adachi T, Sugai M, Nakayama KI, Kojima H, Shinkura R. Regulation of selective class switching provides long-term therapeutic benefits for hay fever. JCI insight. 2025;10(23):e190240. https:\/\/doi.org\/10.1172\/jci.insight.190240.","journal-title":"JCI insight"},{"key":"1283_CR65","doi-asserted-by":"crossref","unstructured":"Li J, Morita N, Miura R, Kimura Y, Shinkura R, Kondo T. Intranasal delivery of bryostatin-1 using surface charge-engineered lipid nanoparticles to modulate mucosal defense for allergic rhinitis treatment. Scientific Reports. 2026.","DOI":"10.1038\/s41598-026-43174-8"},{"issue":"3","key":"1283_CR66","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaci.2022.01.016","volume":"149","author":"MH Shamji","year":"2022","unstructured":"Shamji MH, Sharif H, Layhadi JA, Zhu R, Kishore U, Renz H. Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma. J Allergy Clin Immunol. 2022;149(3):791\u2013801.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1283_CR67","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","volume":"142","author":"M Godar","year":"2018","unstructured":"Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, Blanchetot C, Lambrecht BN. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol. 2018;142(4):1185\u2013e11934. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1283_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/ijms23010083","volume":"23","author":"Y Abe","year":"2021","unstructured":"Abe Y, Suga Y, Fukushima K, Ohata H, Niitsu T, Nabeshima H, Nagahama Y, Kida H, Kumanogoh A. Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma. Int J Mol Sci. 2021;23(1):83. https:\/\/doi.org\/10.3390\/ijms23010083.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1283_CR69","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3390\/jpm13111594","volume":"13","author":"L Carriera","year":"2023","unstructured":"Carriera L, Fant\u00f2 M, Martini A, D\u2019Abramo A, Puzio G, Scaramozzino MU, Coppola A. Combination of biological therapy in severe asthma: where we are? J Personalized Med. 2023;13(11):1594.","journal-title":"J Personalized Med"},{"issue":"1","key":"1283_CR70","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/ijms25010182","volume":"25","author":"CY Chen","year":"2023","unstructured":"Chen CY, Wu KH, Guo BC, Lin WY, Chang YJ, Wei CW, Lin MJ, Wu HP. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics. Int J Mol Sci. 2023;25(1):182. https:\/\/doi.org\/10.3390\/ijms25010182.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1283_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s11671-025-04211-z","volume":"20","author":"V Goswami","year":"2025","unstructured":"Goswami V, Sodhi KK, Singh CK. Innovative approaches to asthma treatment: harnessing nanoparticle technology. Discover Nano. 2025;20(1):21.","journal-title":"Discover Nano"},{"key":"1283_CR72","doi-asserted-by":"publisher","unstructured":"Indolfi C, Klain A, Miraglia Del Giudice M, De Filippo M, Marseglia A, Marseglia GL, Licari A. The use of biologic therapies in pediatric severe asthma. Expert Rev Respir Med. 2025;1\u201311. https:\/\/doi.org\/10.1080\/17476348.2025.2535182. Advance online publication.","DOI":"10.1080\/17476348.2025.2535182"},{"key":"1283_CR73","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fimmu.2020.01134","volume":"11","author":"G Kardas","year":"2020","unstructured":"Kardas G, Kuna P, Panek M. Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling. Front Immunol. 2020;11:1134. https:\/\/doi.org\/10.3389\/fimmu.2020.01134.","journal-title":"Front Immunol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01283-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:22:48Z","timestamp":1780302168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01283-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01283-4","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not report any original data involving human participants or animals. Therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}